KALARIS THERAPEUTICS INC (KLRS) Stock Fundamental Analysis

NASDAQ:KLRS • US4829291065

10.63 USD
-0.34 (-3.1%)
At close: Feb 25, 2026
10.63 USD
0 (0%)
After Hours: 2/25/2026, 8:25:15 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to KLRS. KLRS was compared to 521 industry peers in the Biotechnology industry. The financial health of KLRS is average, but there are quite some concerns on its profitability. KLRS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • KLRS had negative earnings in the past year.
  • In the past year KLRS has reported a negative cash flow from operations.
  • KLRS had negative earnings in each of the past 5 years.
  • In the past 5 years KLRS always reported negative operating cash flow.
KLRS Yearly Net Income VS EBIT VS OCF VS FCFKLRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

  • With a Return On Assets value of -63.70%, KLRS is not doing good in the industry: 60.08% of the companies in the same industry are doing better.
  • KLRS has a Return On Equity of -123.51%. This is in the lower half of the industry: KLRS underperforms 60.46% of its industry peers.
Industry RankSector Rank
ROA -63.7%
ROE -123.51%
ROIC N/A
ROA(3y)-70.08%
ROA(5y)-57.81%
ROE(3y)-85.85%
ROE(5y)-70.73%
ROIC(3y)N/A
ROIC(5y)N/A
KLRS Yearly ROA, ROE, ROICKLRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for KLRS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KLRS Yearly Profit, Operating, Gross MarginsKLRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • KLRS has less shares outstanding than it did 1 year ago.
  • KLRS has less shares outstanding than it did 5 years ago.
  • KLRS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KLRS Yearly Shares OutstandingKLRS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
KLRS Yearly Total Debt VS Total AssetsKLRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • KLRS has an Altman-Z score of -0.72. This is a bad value and indicates that KLRS is not financially healthy and even has some risk of bankruptcy.
  • KLRS has a Altman-Z score (-0.72) which is comparable to the rest of the industry.
  • KLRS has a Debt/Equity ratio of 0.77. This is a neutral value indicating KLRS is somewhat dependend on debt financing.
  • KLRS's Debt to Equity ratio of 0.77 is on the low side compared to the rest of the industry. KLRS is outperformed by 71.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF N/A
Altman-Z -0.72
ROIC/WACCN/A
WACCN/A
KLRS Yearly LT Debt VS Equity VS FCFKLRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 12.89 indicates that KLRS has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 12.89, KLRS belongs to the best of the industry, outperforming 87.72% of the companies in the same industry.
  • A Quick Ratio of 12.89 indicates that KLRS has no problem at all paying its short term obligations.
  • The Quick ratio of KLRS (12.89) is better than 87.72% of its industry peers.
Industry RankSector Rank
Current Ratio 12.89
Quick Ratio 12.89
KLRS Yearly Current Assets VS Current LiabilitesKLRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • KLRS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -36.86%.
EPS 1Y (TTM)-36.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1490%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, KLRS will show a very negative growth in Earnings Per Share. The EPS will decrease by -30.54% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-644.22%
EPS Next 2Y-123.5%
EPS Next 3Y-47.76%
EPS Next 5Y-30.54%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KLRS Yearly Revenue VS EstimatesKLRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2021 2027 2029 2030 2031 2032 2033 100M 200M 300M
KLRS Yearly EPS VS EstimatesKLRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -20 -40 -60 -80 -100

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for KLRS. In the last year negative earnings were reported.
  • Also next year KLRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KLRS Price Earnings VS Forward Price EarningsKLRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KLRS Per share dataKLRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

  • A cheap valuation may be justified as KLRS's earnings are expected to decrease with -47.76% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-123.5%
EPS Next 3Y-47.76%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for KLRS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

KALARIS THERAPEUTICS INC

NASDAQ:KLRS (2/25/2026, 8:25:15 PM)

After market: 10.63 0 (0%)

10.63

-0.34 (-3.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-05
Inst Owners78.84%
Inst Owner Change35.47%
Ins Owners5.88%
Ins Owner Change0%
Market Cap198.78M
Revenue(TTM)N/A
Net Income(TTM)-51.71M
Analysts85
Price Target18.97 (78.46%)
Short Float %5.56%
Short Ratio8.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.56%
Min EPS beat(2)-15.01%
Max EPS beat(2)3.88%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)9.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)19.15%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.75
P/tB 4.75
EV/EBITDA N/A
EPS(TTM)-7.39
EYN/A
EPS(NY)-2.53
Fwd EYN/A
FCF(TTM)-1.88
FCFYN/A
OCF(TTM)-1.87
OCFYN/A
SpS0
BVpS2.24
TBVpS2.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -63.7%
ROE -123.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-70.08%
ROA(5y)-57.81%
ROE(3y)-85.85%
ROE(5y)-70.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.89
Quick Ratio 12.89
Altman-Z -0.72
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-36.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1490%
EPS Next Y-644.22%
EPS Next 2Y-123.5%
EPS Next 3Y-47.76%
EPS Next 5Y-30.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y30.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y71.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.05%
OCF growth 3YN/A
OCF growth 5YN/A

KALARIS THERAPEUTICS INC / KLRS FAQ

What is the ChartMill fundamental rating of KALARIS THERAPEUTICS INC (KLRS) stock?

ChartMill assigns a fundamental rating of 1 / 10 to KLRS.


What is the valuation status of KALARIS THERAPEUTICS INC (KLRS) stock?

ChartMill assigns a valuation rating of 0 / 10 to KALARIS THERAPEUTICS INC (KLRS). This can be considered as Overvalued.


What is the profitability of KLRS stock?

KALARIS THERAPEUTICS INC (KLRS) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for KLRS stock?

The Earnings per Share (EPS) of KALARIS THERAPEUTICS INC (KLRS) is expected to decline by -644.22% in the next year.